Pre-recorded Conference Call to Follow at 1:30 p.m. PDT/4:30 p.m EDT Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. "This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," stated Jennifer Ernst, CEO of Tivic Health. "The first prong is the aggressive steps we have taken to improve the economics of the ClearUP product line -- our comme

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomic nervous system (ANS) function. These include the frequency and the duration of potential treatments. Tivic Health plans to use these results to prioritize clinical indications that the company expects to carry forward into further

Patents cover methods used to identify key treatment points and dynamically personalize simulation Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes these validations are an important step toward securing the foundation for an international market position. Newly validated patents in Great Britain, Germany and France: European Patent EP3615133, both titled "Adaptive Trigger For a Microcurrent Stimulation Device" protects device and methods that the company uses

– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be submitted to [email protected] by November 11. Conference Call Details: Toll Free: 877-545-0523 International: 973-528-0016 Access Code: 507355 Webcast Link

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the first study subject has been enrolled in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation device. The study, being run by The Feinstein Institute of Bioelectronic Medicine, will identify device parameters, including frequency and duration of treatment, that optimally influence autonomic nervous system (ANS) function. The results will be used to inform clinical indication priority and commercial development. Enrollment is expected to be complete by early December. "The effectiveness of Tivic's non-inva

- Presentation will highlight Tivic Health's recent advancements in vagus nerve stimulation - Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that CEO Jennifer Ernst will presenting at the upcoming BioFuture 2024 Conference in New York, October 28-30. Ms. Ernst's presentation, Tuesday, October 29 at 2:30 p.m. EDT, will focus on the company's advances in bioelectronic medicine, including its recently released data on a new approach to vagus nerve stimulation. "This year, BioFuture 2024 has a strong focus on bioelectronic medicine, with industry leaders taking the stage," highlighted Jennifer Ernst, CEO

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it has received approval from The Feinstein Institutes' Institutional Review Board for the next phase of clinical work on its non-invasive cervical vagus nerve stimulation ("ncVNS") approach. This clinical research collaboration with Feinstein is designed to advance the development of Tivic Health's ncVNS technology by refining and optimizing stimulation parameters. Physiological measurements will be used to enhance device performance and refine specifications such as electrode positioning and electrical waveform parameters. The dat

Partners with leading growth strategy firm, Fletcher Spaght Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it has partnered with Fletcher Spaght ("FSI"), a leading healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation ("ncVNS"). Polaris Market Research estimates the global vagus nerve stimulation market will grow from $8.59 billion in 2021 to $21.3 billion in 2030, a 10.6% CAGR over the forecast period. Additionally, IDTechEx has forecast peripheral nerve stimulation, the segment targeted by Tivic Heal

Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its second quarter 2024 financial results and discussed growth strategies based on its investments in vagus nerve stimulation ("VNS"). "This quarter is the start of a potentially transformational period for Tivic. We announced the results of our successful Phase 1 trial of a new approach to non-invasive vagus nerve stimulation. We are partnering with The Feinstein Institute of Bioelectronic Medicine for optimization, and we are continuing to build our intellectual property portfolio in an area of significant potential value to the company and

10-Q - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

1-A/A - Tivic Health Systems, Inc. (0001787740) (Filer)

1-A/A - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

424B5 - Tivic Health Systems, Inc. (0001787740) (Filer)

1-A - Tivic Health Systems, Inc. (0001787740) (Filer)

10-Q - Tivic Health Systems, Inc. (0001787740) (Filer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

3 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

Kimberly Bambach, Ms. Wolf's predecessor, continues with Tivic as advisor focused on strategic transactions and special projects Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, is pleased to announce the appointment of Lisa Wolf as Interim Chief Financial Officer (CFO) of the company, effective October 1, 2024. Ms. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Ms. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. "Lisa has served as a senior member of Tivic's finance team for over two

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of veteran Kimberly Bambach to serve as Interim Chief Financial Officer of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. These additions aim to strengthen the company's financial foundation and bring growth and M&A expertise to the team. Ms. Bambach brings over 30 years of financial leadership experience in both public and private companies across industries. Her background includes financial leadership in medical and retail markets, manufacturing, wholesale distrib

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G/A - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

SC 13G - Tivic Health Systems, Inc. (0001787740) (Subject)

Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company

US Patent 12,011,592 and European Patent EP3615133, both titled "Adaptive Trigger For a Microcurrent Stimulation Device", protect device and methods that the company uses to identify preferred treatment points and trigger a treatment mode. Triggers can be programmed in various ways to improve device performance and ease of use.European Patent EP3615134 entitled "Sinus Treatment Device With Adaptive Circuit" protects the device and methods that the company uses to dynamically adjust the stimulation voltage that is applied during a treatment phase, allowing for dynamic personalization of treatment. The dynamic changes in stimulation help to maximize comfort, enhance device performance, and enr

Gainers OneMedNet (NASDAQ:ONMD) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. 23andMe Holding (NASDAQ:ME) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. Cue Health (NASDAQ:HLTH) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 9.01% to $1.39. The market value of their outstanding s

Tivic Health® Systems, Inc. (("Tivic Health", NASDAQ:TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today it has initiated the second phase of its clinical work to advance its novel non-invasive cervical vagus nerve stimulation ("ncVNS"). The company has entered into a collaboration agreement with The Feinstein Institutes for Medical Research at Northwell Health to optimize its ncVNS device therapy for use in specific clinical indications.Tivic Health will conduct a second 20-person clinical trial in collaboration with Theodoros Zanos, Ph.D., Associate Professor in the Institute of Bioelectronic Medicine and Head of the Neural and Data Science

U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping over 200 points on Thursday. The Dow traded up 0.63% to 39,300.69 while the NASDAQ rose 0.18% to 16,331.58. The S&P 500 also rose, gaining, 0.32% to 5,204.48       . Check This Out: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday Leading and Lagging SectorsReal estate shares rose by 2% on Thursday. In trading on Thursday, information technology shares fell by 0.3%. Top Headline Roblox Corp (NYSE:RBLX) posted better-than-expected first-quarter financial results, but issued weak guidance. Roblox reported fiscal first-quarter 2024 bookings growth of 19% year-on-year to $92

Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duolingo reported quarterly earnings of 57 cents per share which beat the analyst consensus estimate of 27 cents by 111.11%. Quarterly sales came in at $167.6 million which beat the analyst consensus estimate of $165.677 million and is a 44.91% increase from the same period last year, according to data from Benzinga Pro. Duolingo sees second-quarter revenues of between $175 million and $177.5 million, versus the $176.9 million estimate and full-year 2024 revenues of between $726.5 million and $735.5 million, versus the $728.23 million estimate. Du

Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out today. Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 36.28% to $1.02. The market value of their outstanding shares is at $154.2 million. The company's, Q1 earnings came out yesterday. G1 Therapeutics (NASDAQ:GTHX) shares rose 35.08% to $5.79. The company's market cap stands at $302.9 million. Vaccinex (NASDAQ:VCNX) shares rose 31.75% to $7.51. The market value of their outstanding shares is at $11.8 million. Zai Lab (NASDAQ:ZLAB) stock increased by 25.28% to $20.76. The company's

Tivic Health Systems Inc (NASDAQ:TIVC) shares are trading lower by 61% to $0.52 during Thursday’s session after the company disclosed the pricing of its public offering. The offering includes 4.710 million shares of common stock, along with Series A and Series B warrants to purchase additional shares. Each share and accompanying warrants are priced at $0.85. The Series A warrants are exercisable immediately and expire in one year, while the Series B warrants expire in five years. Maxim Group LLC is the sole placement agent for the offering. The company anticipates gross proceeds of approximately $4 million, pending customary closing conditions, with the closing expected around May 13.

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Thursday. The Dow traded up 0.48% to 39,244.53 while the NASDAQ rose 0.32% to 16,354.20. The S&P 500 also rose, gaining, 0.37% to 5,206.94       . Check This Out: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday Leading and Lagging SectorsReal estate shares rose by 1.7% on Thursday. In trading on Thursday, information technology shares fell by 0.2%. Top Headline US Foods Holding Corp (NYSE:USFD) posted better-than-expected first-quarter financial results on Thursday. US Foods reported first-quarter FY24 sales growth of 4.8% year-on-year to $8.95 billion,